No increase in NHS prescription fees for the first time in three years The government has announced that the single item prescription charge for 2025/2026 will remain at £9.90.…
Community pharmacy funding boosted by £617m in two-year contract Community Pharmacy England has announced that a £193m write-off of historic margin overspend has also been agreed with the government.…
RPS members vote ‘yes’ to becoming Royal College of Pharmacy The Royal Pharmaceutical Society will become a royal college by spring 2026 after 71.1% of members who voted were in favour of the proposal.…
What does the assisted dying legislation mean for pharmacy? The Terminally Ill Adults (End of Life) Bill still has a long way to go before becoming law and pharmacy organisations have unresolved questions about what it might mean for pharmacy practice.…
UK medicines regulation disincentivising investment in research development, finds survey The Association of the British Pharmaceutical Industry’s survey results accompany 12 recommendations for improving the Medicines and Healthcare Products Regulatory Agency’s effectiveness as a UK medicines regulator.…
Will reshoring medicines manufacturing solve shortages in the UK? In the United States and some European countries, drug manufacturing is being brought home to mitigate shortages of critical medicines, but would similar action in the UK shore up supply resilience?…
NICE overturns decision on blood cancer treatment elranatamab Elranatamab is now recommended as a fourth-line treatment for relapsed and refractory multiple myeloma, according to updated guidance from the National Institute for Health and Care Excellence.…
Free pharmacy advice saves 38 million GP appointments a year, CPE audit finds Just over half of patients given unfunded pharmacy consultations said they would otherwise have contacted their GP.…
High deprivation areas given funding to boost structured medication reviews, says HIN The Health Innovation Network said that 25 primary care networks would be funded to provide supportive materials that had been shown to improve SMR outcomes.…
NICE rejects second Alzheimer’s disease treatment for NHS use Clinical trial evidence reveals that there are “significant health risks” linked to donanemab, with a third of patients experiencing amyloid-related imaging abnormalities as a result of brain swelling and bleeding.…